Moderate alcohol consumption increases insulin sensitivity and ADIPOQ expression in postmenopausal women: a randomised, crossover trial by Joosten, M. M. et al.
ARTICLE
Moderate alcohol consumption increases insulin sensitivity
and ADIPOQ expression in postmenopausal women:
a randomised, crossover trial
M. M. Joosten & J. W. J. Beulens & S. Kersten &
H. F. J. Hendriks
Received: 7 March 2008 /Accepted: 7 April 2008 /Published online: 27 May 2008
# The Author(s) 2008
Abstract
Aims/hypothesis To determine whether 6 weeks of daily,
moderate alcohol consumption increases expression of the
gene encoding adiponectin (ADIPOQ) and plasma levels of
the protein, and improves insulin sensitivity in postmeno-
pausal women.
Methods In a randomised, open-label, crossover trial con-
ducted in the Netherlands, 36 apparently healthy postmen-
opausal women who were habitual alcohol consumers,
received 250 ml white wine (∼25 g alcohol/day) or 250 ml
of white grape juice (control) daily during dinner for
6 weeks. Randomisation to treatment allocation occurred
according to BMI. Insulin sensitivity and ADIPOQ mRNA
and plasma adiponectin levels were measured at the end of
both periods. Insulin sensitivity was estimated using the
homeostasis model assessment of insulin resistance
(HOMA-IR). Levels of ADIPOQ mRNA in subcutaneous
adipose tissue were determined by RT-PCR.
Results All subjects completed the study. Six weeks of white
wine consumption reduced fasting insulin (mean±SEM 40.0
±3.4 vs 46.5±3.4 pmol/l; p<0.01) and HOMA-IR (1.42±
0.13 vs 1.64±0.13; p=0.02) compared with 6 weeks of
grape juice consumption. ADIPOQ mRNA levels (1.09±
0.15 vs 0.98±0.15; p=0.04) and plasma levels of total (13.1
±0.8 vs 12.0±0.8 μg/ml; p<0.001) and high molecular
weight (HMW) adiponectin (9.9±1.2 vs 8.8±1.2 μg/ml; p=
0.02) significantly increased after alcohol compared with
juice consumption. Changes in ADIPOQ mRNA levels
correlated with changes in plasma levels of total adiponectin
(ρ=0.46; p<0.01). Both fasting triacylglycerol (8.2%; p=
0.04) and LDL-cholesterol levels (7.8%; p<0.0001) de-
creased, whereas HDL-cholesterol increased (7.0%; p<
0.0001) after prolonged moderate alcohol intake. No notable
adverse effects were reported.
Conclusions/interpretation Moderate alcohol consumption
for 6 weeks improves insulin sensitivity, adiponectin levels
and lipid profile in postmenopausal women. Furthermore,
these data suggest a transcriptional mechanism leading to
the alcohol-induced increase in adiponectin plasma levels.
Trial registration: ClinicalTrials.gov ID no.: NCT00285909
Funding: Partly funded by the Dutch Foundation for
Alcohol Research (SAR).
Keywords Adiponectin.Alcoholconsumption.
Geneexpression.Highmolecularweightadiponectin.
Insulin sensitivity.Lipidprofile.Peroxisomeproliferator-
activated receptorgamma.Postmenopausalwomen
Abbreviations
EtG ethyl glucuronide
HMW high molecular weight
HOMA-IR homeostasis model assessment
of insulin resistance
PAI-1 plasminogen activator inhibitor 1
PPAR peroxisome proliferator-activated receptor
Diabetologia (2008) 51:1375–1381
DOI 10.1007/s00125-008-1031-y
M. M. Joosten (*):J. W. J. Beulens:H. F. J. Hendriks
Business Unit Biosciences, TNO Quality of Life,
P. O. Box 360, 3700 AJ Zeist, the Netherlands
e-mail: michel.joosten@wur.nl
e-mail: michel.joosten@tno.nl
M. M. Joosten: J. W. J. Beulens: S. Kersten
Division of Human Nutrition, Wageningen University,
Wageningen, the NetherlandsIntroduction
Moderate alcohol consumption has consistently been
associated with a decreased risk of type 2 diabetes
compared with abstaining and excessive drinking [1, 2].
The reason for the lower risk of type 2 diabetes is not
entirely clear but a plausible explanation seems to be
improved insulin sensitivity [3]. However, so far only one
randomised controlled trial among postmenopausal women
has confirmed this notion [4]. Other studies, mainly
performed among young male populations, failed to detect
such effects [5–12].
Adiponectin, an adipose tissue-derived hormone, is
thought to play an important role in the regulation of
insulin sensitivity and glucose and lipid metabolism [13].
Its plasma levels are positively associated with insulin
sensitivity [14] and are inversely associated with impaired
glucose metabolism and type 2 diabetes [15–17]. Further-
more, observational studies revealed an association between
moderate alcohol consumption, adiponectin concentrations
and insulin sensitivity [18, 19]. Randomised controlled
trials also showed a significant increase in the circulating
levels of both total and high molecular weight (HMW)
adiponectin [6–8] after a period of moderate alcohol
consumption compared with abstention.
However, the mechanism by which moderate alcohol
consumption increases adiponectin levels is unknown.
Synthesis of adiponectin is controlled by peroxisome
proliferator-activated receptor γ (PPAR-γ) activation,
which functions as a transcriptional regulator [20]. Low
doses of alcohol have been shown to alter the expression of
the genes encoding tissue plasminogen activator (PLAT)
and plasminogen activator inhibitor type-1 (PAI-1 also
known as SERPINE1)[ 21]. Like adiponectin, these markers
are affected by moderate alcohol consumption and activated
by PPAR-γ [22].
Consequently, we investigated whether moderate alcohol
consumption affects expression of the gene encoding
adiponectin (ADIPOQ) and levels of the protein, and
whether it improves insulin sensitivity in postmenopausal
women.
Methods
Study protocol The study used a randomised, open label,
placebo-controlled, crossover design, consisting of two
6 week periods, each preceded by 1 week of washout.
Participants consumed 250 ml of white wine (25 g alcohol;
Chardonnay; Jean d’Alibert, Rieux, France) or alcohol-free
white grape juice (Albert Heijn, Zaandam, the Netherlands)
daily for 6 weeks during dinner. The study was conducted
at TNO (a Dutch acronym for the Netherlands organisa-
tion for applied scientific research) Quality of Life, Zeist,
the Netherlands. The primary objective of the study was
to investigate the effect of moderate alcohol consumption
on PPAR-γ activity and risk markers of metabolic disease,
and it took place between March and June 2006.
Participants were instructed to maintain their habitual body
weight, food pattern and physical activity pattern and were
told to refrain from any alcoholic products during the entire
study (including washout periods) except for alcoholic
beverages supplied by TNO. Of the 77 women who were
screened, 40 were eligible to participate. A total of 36
women were randomly selected and initiated the study.
Allocation to treatment order was randomised according to
BMI. Both white wine and white grape juice contained
300 kJ/100 ml (∼70 kcal/100 ml). Blood and adipose tissue
sampling was done on the last day of each treatment period
after an overnight fast. Compliance was monitored by
weekly measurement of urinary ethyl glucuronide (EtG), a
direct phase II metabolite of ethanol formed by the action of
UDP-glucuronosyl transferase. EtG has been reported to be a
superior marker, with 100% sensitivity as a biomarker of
recent drinking [23]. It persists in the urine up to ∼75–85 h
after the last intake. Additional measures of compliance
were an increase in HDL-cholesterol, daily questionnaires,
and return of empty bottles.
Participants Postmenopausal women were recruited from a
pool of volunteers from TNO Quality of Life and by
advertisements in local newspapers. Eligible participants
consumed between 5 and 21 units of alcohol per week,
were apparently healthy and had an absence of menses for
at least 2 years, a BMI between 18.5 and 35 kg/m
2 and no
family history of alcoholism. Participants gave written
informed consent and received compensation for their
participation. An independent medical ethics committee
(The Medical Ethics Committee of the University Medical
Centre Utrecht) approved the research protocol.
Outcome measures Primary endpoints were markers of
insulin sensitivity, such as homeostasis model assessment of
insulin resistance (HOMA-IR), calculated as [fasting serum
insulin (in μU/l) × fasting serum glucose (in mmol/l)]/22.5
[5], glucose, insulin, and several adiponectin-related meas-
ures, such as ADIPOQ mRNA levels and plasma levels of
total and HMW adiponectin. Secondary variables included
lipid profile (triacylglycerol and HDL- and LDL-cholesterol)
HbA1c and NEFA and correlations between specific outcome
measures.
Analyses and assessment Ethyl glucuronide was deter-
mined in morning urine samples. Urinary samples were
diluted about 20-fold using an internal standard solution.
The resulting solution was analysed using a triple quadru-
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Saint-Quentin en Yvelines, France) with a detection limit of
50 ng/ml. The cut-off limit to assess compliance during
juice intervention for urinary EtG values was set at
>0.25 mg/ml (positive sample), to obtain high sensitivity
but avoid positive results due to unintentional ethanol
exposure. The cut-off limit during wine intervention was set
at EtG <0.5 mg/ml (2.2 μmol/l) (negative sample), as
proposed by Bottcher et al. [24]. Blood samples were
obtained from the antecubital vein of the forearm and
collected in tubes containing clot activator for serum and in
ice-chilled tubes containing or potassium ethylenediamine
tetraacetic acid (K3EDTA) for plasma (Vacutainer Systems,
Becton Dickinson, Plymouth, UK). Blood was centrifuged
for 15 min at 2,000×g at 4°C within 15–30 min after
collection and stored at −80°C. All biochemical determi-
nations in blood were performed at TNO Quality of Life
using Olympus analytical equipment and reagents except
for adiponectin. Plasma total adiponectin concentrations
were determined by RIA (Linco Research, St Charles, MO,
USA) with a mean intra-assay coefficient of variation of
5.0%, and plasma HMW adiponectin levels were determined
by a novel ELISA (Linco Research) with a mean intra-assay
coefficient of variation of 14.1%. LDL-cholesterol was
calculated using the Friedewald formula. Subcutaneous adi-
pose tissue was sampled from the buttock by means of a
Strauss cannula, outer diameter 1.5 mm, and stored at −70°C
until further analysis. Total RNA was extracted from
adipose tissue with TRIzol reagent (Invitrogen, Breda, the
Netherlands); 1 mg total RNA was then reverse-transcribed
with iScript (Bio-Rad, Veenendaal, the Netherlands). cDNA
was PCR-amplified with Platinum Taq DNA polymerase
(Invitrogen) on an iCycler (Bio-Rad) or MyIQ (Bio-Rad)
PCR machine. Expression was standardised to the level of
acidic ribosomal protein ARBP [25]. Primer sequences used
were as follows: ADIPOQ forward, TATCCCCAACATG
CCCATTCG; ADIPOQ reverse, TGGTAGGCAAAGTAG
TACAGCC; PPARG forward, TCCATGCTGTTATGGGT
GAA; PPARG reverse, TCAAAGGAGTGGGAGTGGTC;
ARBP forward, CGGGAAGGCTGTGGTGCTG; ARBP
reverse, GTGAACACAAAGCCCACATTCC.
Statistical analyses Statistical analyses were performed
using the SAS statistical software package (SAS version
8; SAS Institute, Cary, NC, USA). All variables were
compared between treatments with a mixed analysis of
variance model that included terms for treatment, period
and the interaction between period and treatment (indicat-
Table 1 Characteristics of 36 postmenopausal women before inter-
vention
Variable Baseline value
Age (years) 56.5±4.2
Weight (kg) 71.4±10.0
BMI (kg/m
2) 25.4±3.3
Fasting glucose (mmol/l) 5.5 ±0.4
Fasting insulin (pmol/l) 37.4±12.6
Fasting triacylglycerol (mmol/l) 1.21±0.54
HDL-cholesterol (mmol/l) 1.67±0.27
LDL-cholesterol (mmol/l) 3.88±0.60
Total cholesterol (mmol/l) 6.11±0.72
Alkaline phosphatase (U/l) 76.1±19.3
Alanine aminotransferase (U/l) 15.3±8.2
Aspartate aminotransferase (U/l) 20.8±7.4
γ-Glutamyltranspeptidase (U/l) 21.3±11.4
Follicle-stimulating hormone (IU/l) 108.5±41.3
Data are mean±SD
Table 2 Markers of insulin
sensitivity, adiponectin and
lipid profile in 36 postmeno-
pausal women measured at the
end of a 6 week period of
consuming white grape juice or
white wine
Data are mean±SEM
Variable Grape juice White wine p value
Insulin sensitivity
HOMA-IR 1.64±0.13 1.42±0.13 0.02
Fasting insulin (pmol/l) 46.5±3.4 40.0±3.4 <0.01
Fasting glucose (mmol/l) 5.4±0.1 5.4±0.1 0.72
HbA1c (%) 6.0±0.04 5.9±0.04 0.09
Fasting NEFA (mmol/l) 0.43± 0.04 0.44±0.04 0.67
Body weight (kg) 70.4±1.7 71.1±1.7 <0.001
Adiponectin
ADIPOQ/ARBP mRNA (arbitrary units) 0.98±0.15 1.09±0.15 0.04
PPARG/ARBP mRNA (arbitrary units) 0.67±0.09 0.73±0.09 0.13
Fasting total adiponectin (μg/ml) 12.0±0.8 13.1±0.8 <0.001
Fasting HMW adiponectin (μg/ml) 8.8±1.2 9.9±1.2 0.02
Lipid profile
Fasting triacylglycerol (mmol/l) 1.18±0.08 1.03±0.08 0.04
HDL-cholesterol (mmol/l) 1.57±0.04 1.68±0.04 <0.0001
LDL-cholesterol (mmol/l) 3.84±0.12 3.51±0.12 <0.0001
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in the model as a random factor to adjust for changes in
body weight. Correlation coefficients were computed
according to Spearman rank order to assess associations
between intervention-induced changes in outcome meas-
ures. Based on a study by Arvidsson et al. [26], a sample
size of 36 was considered sufficient to detect a 20%
difference in ADIPOQ mRNA levels with a power of 80%,
accepting a two-sided α of 0.05. Data are presented as
mean±SEM unless otherwise specified. Statistical signifi-
cance was defined as p<0.05.
Results
General results All 36 postmenopausal women completed
the study. Participants were slightly overweight (BMI 25.4
±3.3 kg/m
2). Mean glucose, insulin, triacylglycerol and
cholesterol concentrations before the intervention indicated
that participants were euglycaemic and normolipidaemic
(Table 1).
Compliance with treatments was assessed by weekly
urinary EtG, revealing two positive samples during the
juice-drinking period and six negative samples during the
wine-drinking period out of the 468 samples analysed
(overall compliance 98.3%). Another indicator of compli-
ance was the 7.0% higher level of HDL-cholesterol after
wine consumption compared with the value after juice
consumption (Table 2).
No significant (p>0.05) carryover effects, as assessed by
interaction between treatment and period effects, were
observed for any outcome measures. Treatment means of
variables and p values estimated from models with period
effects were very similar to those obtained from models
without a period effect, and we report the results of the
latter. Mean body weight was 0.7 kg higher (p<0.001) at
the end of the wine-drinking period than at the end of the
juice-drinking period (Table 2). Results were adjusted for
this difference in body weight but did not essentially change
them. Therefore, unadjusted results are presented here.
Insulin sensitivity Fasting serum insulin concentration was
lower (by 12.3%; p<0.01) and the HbA1c percentage
tended to be lower (p=0.09) after 6 weeks of moderate
alcohol consumption than after 6 weeks of abstention.
Insulin sensitivity, as expressed by the HOMA-IR index,
improved by 11.9% (p=0.02) after white wine consumption
compared with that following juice consumption. However,
serum glucose and NEFA concentrations did not differ
significantly between the two interventions at the end of the
intervention period (Table 2).
Adiponectin There was a significant increase in the relative
ADIPOQ mRNA levels in subcutaneous adipose tissue
(27.7%; p=0.04) of women who consumed alcohol in
moderation for 6 weeks compared with those who
consumed juice. Consistently, the ratio of PPARG/ARBP
mRNA levels also tended to increase, although not
significantly (p=0.13), after the alcohol treatment. Plasma
protein levels of total adiponectin (10.6%; p<0.001) and
HMW adiponectin (15.8%; p=0.02) increased significantly
after consuming white wine, rather than juice, for 6 weeks
(Table 2).
Lipid profile Besides a significant increase in HDL-cholesterol,
changes in lipid profile were further characterised by
significantly lower levels of LDL-cholesterol (7.8%; p<
0.001) and triacylglycerol (8.2%; p=0.04) after the wine-
drinking period compared with the juice-drinking period
(Table 2).
Correlations Changes in ADIPOQ mRNA levels due to
alcohol consumption correlated positively with changes in
PPARG mRNA levels (ρ=0.76; p<0.001) and with changes
in the plasma protein level of total adiponectin (ρ=0.46; p<
0.01), but not with changes in plasma levels of HMW
adiponectin (ρ=−0.25; p=0.15). No significant correlations
were found between changes in HOMA-IR and changes in
plasma levels of total adiponectin (ρ=0.27; p=0.11) or
HMW adiponectin (ρ=−0.18; p=0.29). Furthermore,
changes in HDL-cholesterol correlated significantly with
changes in total adiponectin (ρ=0.47; p<0.01) but not with
HMW adiponectin levels (ρ=0.13; p=0.44).
Discussion
The primary findings of this study are that daily, moderate
alcohol intake improves insulin sensitivity and lipid profile
in postmenopausal women. Furthermore, ADIPOQ mRNA
levels in subcutaneous adipose tissue along with plasma
levels of total and HMW adiponectin increased after
moderate alcohol consumption. Moreover, changes in
ADIPOQ mRNA levels correlated with changes in plasma
total adiponectin, indicating that prolonged moderate
alcohol intake increases circulating adiponectin through
increased gene expression. However, improvements in
insulin sensitivity were not associated with increased
plasma adiponectin levels (HMW and total) after moderate
alcohol consumption in these women.
A strength of this study is its randomised crossover
design. Another strength is that we assessed compliance to
study treatment several times in different ways throughout
the study and observed no significant deviations. Several
1378 Diabetologia (2008) 51:1375–1381limitations warrant consideration. A slightly lower body
weight was observed after the juice intervention compared
with the alcohol intervention. However, lower body weight
is associated with improved insulin sensitivity and thus
could have only affected the results towards no alcohol-
induced improvement in insulin sensitivity. In the present
study, only subcutaneous adipose tissue samples were used
to determine ADIPOQ mRNA levels. Studies demonstrated
that ADIPOQ mRNA levels were higher [27, 28] or not
different [29] in subcutaneous compared with visceral
adipose tissue in lean and obese participants. Furthermore,
studies in human adipose tissue showed increased [30]
as well as similar [31] ADIPOQ mRNA and in vitro
adiponectin secretion levels from subcutaneous compared
with omental adipocytes. Subcutaneous adipose tissue thus
appears to be at least as important as omental adipose tissue
for circulating plasma adiponectin levels.
The observed changes in insulin sensitivity after
prolonged moderate alcohol intake are in accordance with
a study by Davies et al. [4] in which moderate alcohol
consumption in postmenopausal women for 8 weeks
decreased fasting insulin and triacylglycerol levels—both
independent risk factors for type 2 diabetes—and improved
insulin sensitivity. However, other clinical trials did not find
a change in fasting insulin levels [9] and triacylglycerol
levels [32, 33] or in insulin sensitivity after moderate
alcohol consumption [5–8, 10, 11], whereas levels of total
adiponectin [6, 7] and HMW adiponectin [8] did increase.
Differences in the designs used in these clinical trials are
numerous. However, studies that did observe an effect on
markers of insulin sensitivity after moderate alcohol
consumption were all performed in middle-aged [4],
relatively insulin-resistant [6]o rd i a b e t i cp e o p l e[ 34, 35].
This suggests that the effect of moderate alcohol intake on
insulin sensitivity is more pronounced in people with
(slightly) impaired glucose tolerance rather than young and
glucose-tolerant people. Moreover, most interventions that
did not observe a link between alcohol and insulin
sensitivity involved only 30 [5, 12]o re v e nf e w e r[ 6–
8,11] days of consecutive alcohol consumption, while this
study and the studies of Davies et al. [4] and Shai et al.
[34] lasted 6, 8 and 12 weeks respectively. This indicates
that a longer duration of alcohol consumption may be
needed to exert an effect on insulin sensitivity. Finally, the
relation between moderate alcohol intake and insulin
sensitivity might be influenced by sex, since the associa-
tion between alcohol consumption and type 2 diabetes
appears to be stronger in women than in men, as
observed in some observational studies [1]. This sex
difference may be explained partly by changes associated
with menopause, which may mediate the relation between
alcohol and triacylglycerol levels, the latter being an
independent risk factor for type 2 diabetes [36]. Compared
with postmenopausal non-drinkers, postmenopausal
drinkers have lower triacylglycerol levels, whereas male
drinkers have higher triacylglycerol levels compared with
male abstainers [37].
Intervention-associated changes in ADIPOQ mRNA in
subcutaneous adipose tissue correlated with changes in
plasma protein levels of total adiponectin. In line with this
are cross-sectional studies [38, 39] showing associations
between subcutaneous ADIPOQ mRNA levels and plasma
levels of adiponectin. This finding suggests that the
alcohol-induced increase in plasma adiponectin levels is
mediated by de novo synthesis rather than decreased renal
function [40] or post-transcriptional regulation [41].
Changes in plasma HMW adiponectin did not correlate
with changes in ADIPOQ mRNA levels. However, the
formation of multimer oligomers of HMW adiponectin is
influenced by several post-translational modifications [42],
which can account for the absence of such a correlation.
Adiponectin synthesis is under the control of the
transcription factor PPAR-γ [20]. PPAR-γ ligands induce
expression of ADIPOQ via direct binding of the PPAR-γ/
retinoid X receptor heterodimer to the PPAR-responsive
element in the human ADIPOQ promoter. We indeed
observed a trend for increased PPARG mRNA levels after
the alcohol intervention. However, our sample size of 36
participants was anticipated to detect a 20% change in
mRNA levels. As the intervention gave rise to a change of
only 9% in PPARG mRNA, our study was underpowered to
detect a significant difference. Besides this trend for
increased PPAR levels, we also found a strong correlation
between intervention-associated changes in levels of
PPARG and ADIPOQ mRNAs. Furthermore, previous
research has shown that PAI-1 expression and PAI-1 protein
levels increase after alcohol consumption [21]. PAI-1
expression is also regulated by PPAR-γ [22]. It thus seems
plausible that moderate alcohol use might alter ADIPOQ
expression and, consequently, adiponectin protein levels,
also in a PPAR-γ-mediated manner.
Consistent with previous findings in young and middle-
aged men [6, 7], we now report that total adiponectin
plasma levels also increase in postmenopausal women after
moderate alcohol consumption. Moreover, we found that
the HMW form of plasma adiponectin also increased after
6 weeks of alcohol consumption. The increase in HMW
adiponectin after moderate alcohol consumption is in line
with a previous study in which a trend was observed [8]. In
the present study, however, we used a more sensitive and
precise method to quantify HMW adiponectin—ELISA
instead of quantitative western blotting.
The observed changes in insulin sensitivity as measured
by HOMA-IR did not correlate with the alcohol-induced
changes in total or HMW adiponectin, the latter of which is
proposed to be a better predictor of insulin sensitivity [43].
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tions, such as weight loss [44] and exercise interventions
[45], and with previous observations of our group [7, 8]
which showed increased adiponectin plasma levels without
changesininsulinsensitivity.Inthisstudywedidfindaneffect
of alcohol on insulin sensitivity irrespective of changes in
adiponectin levels. The present results may suggest a possible
independent effect of alcohol on insulin sensitivity in addition
to an adiponectin-mediated effect on insulin sensitivity.
Looking at our cross-sectional data, we did observe
correlations between HOMA-IR and adiponectin levels
after both alcohol and placebo treatment (data not shown).
This is in line with published literature in which associa-
tions between adiponectin and insulin sensitivity have been
shown consistently [14–17]. Possibly, increased adiponec-
tin levels partly explain the improved insulin sensitivity
seen among moderate alcohol consumers [18, 19]. Studies
have revealed that circulating adiponectin levels are
inversely associated with markers of inflammation [39,
46, 47], whereas low-grade inflammation is thought to
contribute to insulin resistance [48]. Therefore, adiponectin
may lead to improved insulin sensitivity through effects on
inflammatory markers.
In conclusion, the results of the present study demon-
strate that 6 weeks of moderate alcohol consumption
improves insulin sensitivity and the lipid profile in
postmenopausal women. Furthermore, moderate alcohol
consumption increases subcutaneous adipose ADIPOQ
mRNA levels and plasma levels of adiponectin. This
suggests that the alcohol-induced increase in adiponectin
is attributable, at least in part, to transcriptional alterations
in adipose tissue. The observed improvements in insulin
sensitivity, lipid profile and adiponectin levels when
consuming 2.5 standard drinks per day may reduce the risk
of type 2 diabetes and cardiovascular disease in postmen-
opausal women. Despite these potentially beneficial find-
ings, the scientific literature indicates that alcohol drinking
may also have detrimental effects on health [49]. Both
potential benefits and risks should be taken into consider-
ation when counselling people about consumption.
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